Wire · opportunities
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 September 2026 · Fusion42 review
The FDA has cleared the IND application for IASO208, a novel CD20-targeted in vivo CAR-T therapy that generates CAR-T cells directly within patients without leukapheresis or lymphodepletion, enabling a phase 1b trial in the US for relapsed/refractory B-cell non-Hodgkin lymphoma.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You face a new competitor opening US trials for a streamlined CAR-T therapy that skips traditional manufacturing hurdles. This clearance signals China-originated in vivo CAR-T tech can now compete directly in your market.
◆ Coverage
2 sources · 16 Sep 2026
◆ Related on Wire
◆ Topics